ADMP News and Press, Adamis Pharmaceuticals Corporation From 03/31/22

SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the ye...

LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and availability of ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL. ZIMHI is a high-dose nalo...

ADMP, AEHR, ASTR, ASTS, BB, BIOC, BLND, CALA, DARE, DCT, FUV, MARK, NBEV, NCNO, NVVE, PL, PL, PPSI, REED, REKR, OTCQX:SHWZ, SPRO, OTCQX:TPRFF, VERB, VISL, VJET, VTSI For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's...

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investo...

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with high levels of the Omicron v...

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level. The batches...

A Data Safety Monitoring Board has determined that Adamis Pharmaceuticals' (NASDAQ:ADMP) phase 2/3 trial for its COVID-19 candidate tempol can continue without any changes. Shares are up 5% in premarket trading. The decision was reached following an evaluation of an interim analysis...

Adamis Pharmaceuticals (NASDAQ:ADMP) chairman Richard C. Williams to retire effective April 15, 2022. “We admire Dick for his work ethic and wish him all the best in his retirement." said CEO and President, Dr. Dennis J. Carlo Shares -2.64% PM Recentl...

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022. “Dick has provided almost eight years of strategic leadership and committed service to Adamis an...

Adamis Pharmaceuticals (ADMP +1.9%) said the Data Safety Monitoring Board (DSMB) determined that its phase 2/3 trial of Tempol to treat COVID-19 can continue as no safety or clinical concerns were seen following acceleration of patient enrollment in the study. The data from the first 50 ...